< Back to Services
The Compound Management and Screening Center (COMAS) has been implemented at the Max Planck Institute of Molecular Physiology in Dortmund as the central substance library of the Max Planck Society.
Thus, the exploitation of the full potential of the compound library including over 240.000 low molecular compounds will lead to the identification of chemical probes for basic science and medical applications.
The major goal is to identify bioactive compounds as modulators of biological functions by using biochemical and cell-based high-throughput assays. These molecular probes should help to better understand the role of cellular lead structures in basic research. Furthermore, identified active substances can serve as a starting point for the development of pharmacologically active substances.The COMAS automated -20°C compound store guarantees a state-of-the-art infrastructure for the storage and distribution of chemical compounds. In addition, state-of-the-art screening robots capable of biochemical and cell-based screening have been installed. COMAS screening results will be merged and analyzed by cheminformatic tools, creating an additional benefit for the optimal recovery of the results. Thus, COMAS will enable the successful translation of basic research of the Max Planck Society to medical applications.
Dr. Sonja Sievers